Louis Hernandez, MD
Family Medicine · Madera, CANPI 1730295189
Payments from drug & device makers
Across 335 payments — averaging $15.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- Amarin Pharma, Inc.$683
- AstraZeneca$527
- Ardelyx, Inc.$371
- Pfizer$370
- AbbVie$322
- plus $2K from 24 others
What the payments were for
- Food & beverage$5,294100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 62 | $1,030 |
| Amarin Pharma, Inc. | 73 | $683 |
| AstraZeneca | 30 | $527 |
| Ardelyx, Inc. | 23 | $371 |
| Pfizer | 29 | $370 |
| AbbVie(2 entities) | 19 | $322 |
| Novo Nordisk | 15 | $276 |
| Medtronic | 2 | $166 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $162 |
| Sanofi-aventis U.S. LLC | 11 | $160 |
| Lilly USA, LLC | 10 | $151 |
| Bayer | 6 | $142 |
| Abiomed | 2 | $132 |
| Johnson & Johnson | 7 | $129 |
| Abbott | 4 | $85 |
| Amgen | 4 | $83 |
| Avanir Pharmaceuticals, Inc. | 3 | $63 |
| Mannkind Corporation | 4 | $62 |
| Boehringer Ingelheim | 2 | $59 |
| Merck | 3 | $52 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $38 |
| Exact Sciences | 2 | $37 |
| Biodelivery Sciences International, Inc. | 2 | $36 |
| Baxter Healthcare | 1 | $32 |
| Sunovion Pharmaceuticals Inc. | 2 | $25 |
| Ultragenyx Pharmaceutical Inc. | 1 | $24 |
| Hologic Sales And Service, LLC | 1 | $24 |
| Nevro Corp. | 1 | $22 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Shire North American Group Inc | 1 | $13 |
How this compares
$5,294 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 198 | $162,607 |
| SynjardyEmpagliflozin/Metformin Hcl | 134 | $135,454 |
| JardianceEmpagliflozin | 121 | $128,005 |
| JanuviaSitagliptin Phosphate | 93 | $117,647 |
| TrulicityDulaglutide | 85 | $114,034 |
| OzempicSemaglutide | 99 | $106,514 |
| RybelsusSemaglutide | 65 | $103,450 |
| FarxigaDapagliflozin Propanediol | 91 | $102,362 |
| EliquisApixaban | 59 | $65,514 |
| MounjaroTirzepatide | 36 | $43,737 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 37 | $34,472 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 45 | $32,008 |
| TradjentaLinagliptin | 25 | $30,911 |
| Xigduo XrDapaglifloz Propaned/Metformin | 37 | $26,224 |
| XareltoRivaroxaban | 20 | $24,869 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimSynjardy, Jardiance, Tradjenta, Synjardy Xr | $59 | $313,086304 claims |
| Novo NordiskOzempic, Rybelsus | $276 | $209,964164 claims |
| AbbVieLinzess | $322 | $162,607198 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $151 | $157,771121 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $527 | $129,729134 claims |
| MerckJanuvia | $52 | $117,64793 claims |
| PfizerEliquis | $370 | $65,51459 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $1,030 | $39,02958 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $160 | $34,47237 claims |
| Johnson & JohnsonXarelto | $129 | $24,86920 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.
Other family medicine in Madera
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Augusto FocilOxnard$12.6M
- Jack VuLong Beach$10.1M
- Suzanne FussellOxnard$8.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.